Keywordscarbon-11; 11C-labelling; urea; carbonylation; positron emission tomography; carbon monoxide; positron emission tomography; histone deacetylase; radioligand; imaging; neurodegenerative disease; [18F]flubatine; NCFHEB; [18F]FLBT; radiometabolites; glucuronides; liquid chromatography–tandem mass spectrometry (LC-MS/MS); liver microsomes; positron emission tomography (PET); nicotinic acetylcholine receptors (nAChRs); Phosphodiesterase 2A (PDE2A); secondary messengers; PDE2A radioligands; positron emission tomography (PET); neuroimaging; metabolic stability; micellar liquid chromatography (MLC); targeted alpha therapy; nuclear recoil; in vivo generators; radium; 223Ra; actinium; astatine; bismuth; alpha particle; decay; D2/D3 receptors; hemiparkinsonian rat model; Botulinum neurotoxin A; basal ganglia; striatum; Parkinson’s disease; small animal imaging; PET/CT; [18F]fallypride; MRI; positron emission tomography; microglia; neuroinflammation; zirconium-89; chelator; positron emission tomography; 99mTc-radiopharmaceuticals; radiochemical purity; radiopharmaceuticals quality control; [18F]fluspidine; carcinoma; glioblastoma; melanoma; sigma-1 receptor; dedicated small animal PET/CT; [18F]FEPPA; TSPO; brain inflammation; small-animal PET imaging; radiolabeling; radiotracer metabolism; pemetrexed; folic acid; radiofolate; albumin-binder; SPECT; 177Lu; KB; IGROV-1
